Datopotamab deruxtecan
德达博妥单抗TROP2-directed ADC newly added to the 2026 NRDL Negotiated List (#288) for previously treated HR+/HER2- unresectable or metastatic breast cancer.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字SJ20250021
- Initial Approval Date
- Aug 22, 2025
- Notice Published
- Sep 29, 2026
- MAH
- Daiichi Sankyo / AstraZeneca (第一三共 / 阿斯利康)
- Approved Scope
- 1 initial presentation(s) & 1 supplemental event(s) verified — see table below.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #288 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Restricted to adults with unresectable or metastatic HR-positive, HER2-negative (IHC 0, 1+, or 2+/ISH-) breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting.
- 限既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、人类表皮生长因子受体2(HER2)阴性(IHC 0、IHC 1+或IHC 2+/ISH-)乳腺癌成人患者。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
Approved Products, Dosage Forms & Approval Numbers
2 verified NMPA records| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字SJ20250021 | Powder for Injection (注射剂) 100mg/瓶 | Supplemental Indication Supplemental indication for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor therapy (note: 2026 NRDL covers HR+/HER2- BC only). 适用于不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌(TNBC)成人患者。 | Approved: 2026-09-29 Published: 2026-09-29 | Daiichi Sankyo / AstraZeneca |
| 国药准字SJ20250021 | Powder for Injection (注射剂) 100mg/瓶 | Initial Approval Adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting. 适用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、HER2阴性乳腺癌成人患者。 | Approved: 2025-08-22 Published: 2025-08-22 | Daiichi Sankyo / AstraZeneca |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Added to Negotiated List
Newly added to 2026 NRDL Negotiated List (#288, Class B, *) for adult HR+/HER2- unresectable or metastatic breast cancer after prior ET and ≥1L chemo.
Chinese original: 新增纳入2026版谈判药品第288项(乙类,支付标准*),限既往接受过内分泌治疗且晚期经≥1线化疗的HR阳性HER2阴性乳腺癌。
NHSA · PDF p.148Verified 2026-11-20 - (2026-09-29)NMPA Approval
NMPA Supplemental Indication Approval (国药准字SJ20250021 · 100mg/瓶)
Supplemental indication for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor therapy (note: 2026 NRDL covers HR+/HER2- BC only).
Chinese original: 适用于不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌(TNBC)成人患者。
NMPA · NMPA Supplemental Approval 2026-09-29Verified 2026-11-21 - (2025-08-22)NMPA Approval
NMPA Initial Marketing Approval (国药准字SJ20250021 · 100mg/瓶)
Adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting.
Chinese original: 适用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、HER2阴性乳腺癌成人患者。
NMPA · NMPA Registration SJ20250021Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20